Announcement • Jul 20
Mach7 Technologies Limited to Report Q4, 2026 Results on Jul 29, 2026 Mach7 Technologies Limited announced that they will report Q4, 2026 results on Jul 29, 2026 Announcement • Jun 02
Mach7 Technologies Showcases Enterprise Imaging Innovation and New eUnity Digital Pathology Capabilities At SIIM26 Mach7 Technologies announced its participation in the SIIM26 Annual Meeting + InformaticsTECH Expo, taking place June 10–12, 2026, at the David L. Lawrence Convention Center in Pittsburgh, Pennsylvania. At Booth 608, Mach7 will showcase enterprise imaging solutions designed to help healthcare organizations manage, access, and share medical imaging across the enterprise. Demonstrations and discussions will focus on enterprise imaging workflows, enterprise viewing with Mach7 eUnity, workflow orchestration, VNA modernization strategies, image acquisition workflows, interoperability, and digital pathology capabilities. Attendees will also have the opportunity to learn about recent enhancements to Mach7 eUnity, including capabilities designed to support enterprise imaging workflows across additional imaging specialties, including digital pathology. Digital pathology functionality is currently available only in the United States and is intended for reference and referral use only, not for primary diagnosis. Product availability may vary by market and is subject to applicable regulatory requirements. Recent Insider Transactions • May 27
CEO, MD & Director recently bought AU$89k worth of stock On the 22nd of May, Teri Thomas bought around 200k shares on-market at roughly AU$0.45 per share. This transaction amounted to 57% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth AU$150k. Teri has been a buyer over the last 12 months, purchasing a net total of AU$110k worth in shares. Announcement • Apr 21
Mach7 Technologies Limited to Report Q3, 2026 Results on Apr 24, 2026 Mach7 Technologies Limited announced that they will report Q3, 2026 results at 4:12 PM, AUS Eastern Standard Time on Apr 24, 2026 Announcement • Jan 22
Mach7 Technologies Limited to Report Q2, 2026 Results on Jan 30, 2026 Mach7 Technologies Limited announced that they will report Q2, 2026 results on Jan 30, 2026 Announcement • Oct 23
Mach7 Technologies Limited to Report Q1, 2026 Results on Oct 31, 2025 Mach7 Technologies Limited announced that they will report Q1, 2026 results on Oct 31, 2025 Announcement • Oct 02
Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2025 Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2025. Breakeven Date Change • Aug 28
Forecast to breakeven in 2028 The 4 analysts covering Mach7 Technologies expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 16% per year to 2027. The company is expected to make a profit of AU$900.0k in 2028. Average annual earnings growth of 70% is required to achieve expected profit on schedule. Announcement • Aug 08
Mach7 Technologies Limited to Report Fiscal Year 2025 Results on Aug 27, 2025 Mach7 Technologies Limited announced that they will report fiscal year 2025 results on Aug 27, 2025 Breakeven Date Change • May 01
No longer forecast to breakeven The 4 analysts covering Mach7 Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$2.75m in 2027. New consensus forecast suggests the company will make a loss of AU$2.14m in 2027. Announcement • Apr 14
Mach7 Technologies Limited to Report Q3, 2025 Results on Apr 29, 2025 Mach7 Technologies Limited announced that they will report Q3, 2025 results on Apr 29, 2025 Announcement • Feb 28
Mach7 Technologies Announces Product Launch of the Eunity Diagnostic Image Viewer Using Aws Healthimaging Mach7 Technologies announced a breakthrough in medical imaging access, performance, and cloud enablement with the release of its eUnity Enterprise Diagnostic Viewer, which uses AWS HealthImaging. The release marks a major milestone for Mach7 in its continuing goal of delivering new, impactful offerings to the Healthcare IT sector. Mach7 is a part of the AWS Partner Network (APN), a global community that leverages programs, expertise, and resources to build, market, and sell customer offerings with smart integration to the cloud. The release is a significant innovation with advanced cloud capabilities that allow clinicians to have fast access to patient studies across the healthcare enterprise regardless of acquisition or data source. Key benefits: One visualization experience with the eUnity Zero Footprint Diagnostic Enterprise Viewer; Leverage High-Throughput JPEG 2000 (HTJ2K) utilized with AWS HealthImaging data stores; Federation of multiple archive locations including local storage and multiple AWS HealthImaging data stores. At petabyte scale, data transfer speeds equal to or exceeding traditional local storage models at petabyte scale, using AWS HealthImaging; Allows full control of data to support customized workflows, clinical research, and artificial intelligence (AI) modeling; The ability to segment studies for various reading groups and practices and build privilege-based access strategies for different user groups; Utilize current reading worklist to leverage current IT investments; All images are available from local or cloud data stores with no sacrifice in performance with full diagnostic image quality at sub-second latency. eUnity, using AWS HealthImaging, creates a powerful diagnostic imaging solution for clinicians and IT staff that enables automated, efficient workflows, vast scalability, and cost savings. Breakeven Date Change • Feb 04
Forecast breakeven date pushed back to 2027 The 5 analysts covering Mach7 Technologies previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 49% per year to 2026. The company is expected to make a profit of AU$4.20m in 2027. Average annual earnings growth of 71% is required to achieve expected profit on schedule. Announcement • Jan 31
Mach7 Technologies Limited to Report First Half, 2025 Results on Feb 27, 2025 Mach7 Technologies Limited announced that they will report first half, 2025 results on Feb 27, 2025 Announcement • Jan 30
Mach7 Technologies Limited (ASX:M7T) announces an Equity Buyback for 24,124,104 shares, representing 10% for AUD 5 million. Mach7 Technologies Limited (ASX:M7T) announces a share repurchase program. Under the program, the company will repurchase up to 24,124,104 shares, representing 10% of its issued share capital, for AUD 5 million. The shares will be repurchased at the price no more than 5% above the volume weighted average price of company's shares over the five trading days prior to purchase. The shares repurchased will be cancelled. The program is valid till February 3, 2026. As of January 30, 2025, there are 241,241,047 outstanding shares. Announcement • Jan 21
Mach7 Technologies Limited to Report Q2, 2025 Results on Jan 31, 2025 Mach7 Technologies Limited announced that they will report Q2, 2025 results on Jan 31, 2025 Breakeven Date Change • Dec 24
Forecast breakeven date pushed back to 2027 The 5 analysts covering Mach7 Technologies previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 49% per year to 2026. The company is expected to make a profit of AU$4.20m in 2027. Average annual earnings growth of 71% is required to achieve expected profit on schedule. Announcement • Nov 12
Mach7 Technologies Introduces UnityVue, A Next-Generation Radiology Reading Solution with Groundbreaking Capabilities Mach7 Technologies announced the formal launch of UnityVue, a landmark radiology software platform developed in partnership with NewVue. UnityVue is a pioneering solution which integrates Mach7's well-renown eUnity Enterprise Diagnostic Viewer (eUnity) with NewVue's revolutionary EmpowerSuite Workflow Orchestrator, delivering a comprehensive software platform designed to improve radiology reading workflows. UnityVue consolidates radiology workflows by seamlessly integrating image viewing and worklist management. This cloud-based solution offers radiologists a powerful platform for task prioritization, AI-driven data aggregation, and enhanced diagnostic workflow—all from a single interface. UnityVue's ability to dynamically curate worklists and automate data normalization enhances productivity while reducing administrative burden. UnityVue's key features include cloud-based image access, real-time AI-driven workflow orchestration, automated data normalization, and a unified interface for radiologists to perform their tasks efficiently. With its zero-footprint design, UnityVue allows radiologists to access critical information from any location, enhancing productivity while reducing administrative complexity. Through the launch of UnityVue, Mach7 customers have a future proof, all-in-one solution that not only meets the current demands of radiologists but also anticipates future needs. By solving these critical challenges, healthcare organizations can deploy a platform that enhances job satisfaction for radiologists, improves patient care, and drives better business outcomes. Key Benefits: For Independent Delivery Networks: Unifying PACS: Integrates multiple PACS systems into a single platform, simplifying workflows and reducing inefficiencies. Gradual Cloud Migration: IDNs can migrate to the cloud incrementally, preserving existing systems while modernizing infrastructure. Disaster Recovery: Cloud-based continuity ensures radiologists can continue working during local system outages. Reduced IT Complexity: The zero-footprint design eliminates on-site server requirements and minimizes maintenance. Announcement • Oct 11
Mach7 Technologies Limited to Report Q1, 2025 Results on Oct 31, 2024 Mach7 Technologies Limited announced that they will report Q1, 2025 results on Oct 31, 2024 Announcement • Oct 03
Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2024 Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2024. Breakeven Date Change • Aug 29
Forecast breakeven date pushed back to 2027 The 4 analysts covering Mach7 Technologies previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of AU$2.40m in 2027. Average annual earnings growth of 66% is required to achieve expected profit on schedule. Reported Earnings • Aug 28
Full year 2024 earnings released: AU$0.033 loss per share (vs AU$0.004 loss in FY 2023) Full year 2024 results: AU$0.033 loss per share (further deteriorated from AU$0.004 loss in FY 2023). Revenue: AU$30.0m (flat on FY 2023). Net loss: AU$7.97m (loss widened AU$6.92m from FY 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare Services industry in Australia. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Announcement • Jul 12
Mach7 Technologies Limited to Report Fiscal Year 2024 Results on Aug 28, 2024 Mach7 Technologies Limited announced that they will report fiscal year 2024 results on Aug 28, 2024 Announcement • Jul 10
Mach7 Technologies Limited to Report Q4, 2024 Results on Jul 30, 2024 Mach7 Technologies Limited announced that they will report Q4, 2024 results on Jul 30, 2024 New Risk • Jul 10
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: AU$148.4m (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Buy Or Sell Opportunity • Jul 01
Now 25% undervalued after recent price drop Over the last 90 days, the stock has fallen 11% to AU$0.64. The fair value is estimated to be AU$0.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 40%. Revenue is forecast to grow by 28% in a year. Earnings are forecast to grow by 22% in the next year. Buy Or Sell Opportunity • Jun 25
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 7.9% to AU$0.64. The fair value is estimated to be AU$0.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 40%. Revenue is forecast to grow by 28% in a year. Earnings are forecast to grow by 22% in the next year. Buy Or Sell Opportunity • May 30
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 5.1% to AU$0.66. The fair value is estimated to be AU$0.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 40%. Revenue is forecast to grow by 28% in a year. Earnings are forecast to grow by 22% in the next year. Buy Or Sell Opportunity • Apr 18
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 7.1% to AU$0.65. The fair value is estimated to be AU$0.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 40%. Revenue is forecast to grow by 28% in a year. Earnings are forecast to grow by 22% in the next year. Announcement • Apr 08
Mach7 Technologies Limited to Report Q3, 2024 Results on Apr 24, 2024 Mach7 Technologies Limited announced that they will report Q3, 2024 results on Apr 24, 2024 Announcement • Feb 15
Mach7 Technologies Limited to Report First Half, 2024 Results on Feb 29, 2024 Mach7 Technologies Limited announced that they will report first half, 2024 results on Feb 29, 2024 Breakeven Date Change • Jan 24
Forecast breakeven date pushed back to 2026 The 5 analysts covering Mach7 Technologies previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of AU$3.15m in 2026. Average annual earnings growth of 52% is required to achieve expected profit on schedule. Announcement • Jan 23
Mach7 Technologies Limited to Report Q2, 2024 Results on Jan 31, 2024 Mach7 Technologies Limited announced that they will report Q2, 2024 results on Jan 31, 2024 Board Change • Nov 22
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Independent Non-Executive Director Rob Bazzani was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Nov 18
Mach7 Technologies Limited Appoints Rebecca Thompson as Director Mach7 Technologies Limited announced appointment of Rebecca Thompson as director. Date of appointment is 16 November 2023. Announcement • Oct 23
Mach7 Technologies Limited to Report Q1, 2024 Results on Oct 31, 2023 Mach7 Technologies Limited announced that they will report Q1, 2024 results on Oct 31, 2023 New Risk • Oct 18
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: AU$155.2m (US$98.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Announcement • Sep 22
Mach7 Technologies Limited Announces Board Changes, Effective 16 November 2023 Mach7 Technologies Limited announced that Mr. Philippe Houssiau will retire as Non-Executive Director of the company, effective from the close of the Company's Annual General Meeting on 16 November 2023 and that Ms. Rebecca Thompson has agreed to join the Mach7 Board as an independent Non-Executive Director, following the conclusion of the Company's Annual General Meeting on 16 November 2023. Mr. Houssiau joined the Mach7 Board in January 2021 as an independent Non-Executive Director and has served on the Company's Remuneration and Nomination Committee. As a part of the recently announced Board renewal process Ms Thompson will be joining the Board as a Non-Executive Director. Ms Thompson has deep experience in financial markets with senior roles at global investment banks, most recently at J.P. Morgan, and with listed companies over her 30-year career to date. Since mid-2022 and until her recent appointment as head of investor relations at CSR Limited, Rebecca was a consultant to Mach7. Apart from providing Rebecca with a strong understanding of the Mach7 business and its market dynamics, the relationship has demonstrated Rebecca's professionalism, commercial acumen, compatibility and sound judgement. Rebecca's professional experience spans the property, resources, fintech and charitable sectors with a strong focus on sustainability and ESG. She holds a Bachelor Degree in Economics from the University of Sydney and has a graduate qualification in finance and investment. Breakeven Date Change • Sep 04
Forecast breakeven date pushed back to 2025 The 2 analysts covering Mach7 Technologies previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of AU$3.15m in 2025. Average annual earnings growth of 87% is required to achieve expected profit on schedule. Reported Earnings • Sep 01
Full year 2023 earnings released: AU$0.004 loss per share (vs AU$0.018 loss in FY 2022) Full year 2023 results: AU$0.004 loss per share (improved from AU$0.018 loss in FY 2022). Revenue: AU$30.5m (up 12% from FY 2022). Net loss: AU$1.05m (loss narrowed 75% from FY 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Healthcare Services industry in Australia. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. New Risk • Aug 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company. Announcement • Aug 28
Mach7 Technologies Limited to Report Fiscal Year 2023 Results on Aug 31, 2023 Mach7 Technologies Limited announced that they will report fiscal year 2023 results on Aug 31, 2023 Announcement • Aug 11
Mach7 Technologies Limited, Annual General Meeting, Nov 16, 2023 Mach7 Technologies Limited, Annual General Meeting, Nov 16, 2023. Announcement • Jul 28
Mach7 Technologies Limited to Report Q4, 2023 Results on Jul 31, 2023 Mach7 Technologies Limited announced that they will report Q4, 2023 results on Jul 31, 2023 Buying Opportunity • May 03
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 13%. The fair value is estimated to be AU$0.81, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has declined by 7.2%. Buying Opportunity • Apr 13
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 21%. The fair value is estimated to be AU$0.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has declined by 7.2%. Reported Earnings • Mar 01
First half 2023 earnings released: AU$0.001 loss per share (vs AU$0.002 loss in 1H 2022) First half 2023 results: AU$0.001 loss per share (improved from AU$0.002 loss in 1H 2022). Revenue: AU$16.5m (up 15% from 1H 2022). Net loss: AU$130.4k (loss narrowed 69% from 1H 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Healthcare Services industry in Australia. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Announcement • Feb 01
Mach7 Technologies Limited Announces Change of Company Secretary Mach7 Technologies Limited announced the appointment of Mr. Tony Panther as Company Secretary, effective 1 February 2023, to replace Ms. Veronique Morgan-Smith, following team reassignments at Vistra Australia, the Company's provider of secretarial and corporate compliance services. Mr. Panther is a Chartered Accountant with over 30 years' experience in a variety of fields. Following completion of university commerce and law degrees he worked as an external auditor with a major international chartered accounting firm and has progressed to a range of internal audit, compliance, senior finance, and company secretarial roles with a number of ASX-listed and unlisted public companies and professional services firms, covering financial services, utilities, biotech, IT services, mineral exploration and environmental technologies. He specialises in financial reporting and company secretarial practice. Announcement • Jan 28
Mach7 Technologies Limited Provides Revenue Guidance for the Year 2023 Mach7 Technologies Limited provided revenue guidance for the year 2023. The company expects +20% revenue growth in fiscal year 2023, underpinned by a healthy pipeline and the recognition of revenue from the Trinity Health and Adventist Health sales orders as Mach7's software progressively goes live. Approximately 80-85% of the TCV associated with these contracts is yet to be recognised as revenue. At approximately 70% towards its goal, Mach7 remains confident of achieving its fiscal year 2023 sales order forecast of at least $36 million, which represents a 20% increase on the fiscal year 2022 target of $30 million and +8% on the $33.2 million achieved. Reported Earnings • Aug 30
Full year 2022 earnings released: AU$0.018 loss per share (vs AU$0.04 loss in FY 2021) Full year 2022 results: AU$0.018 loss per share (up from AU$0.04 loss in FY 2021). Revenue: AU$27.1m (up 42% from FY 2021). Net loss: AU$4.17m (loss narrowed 56% from FY 2021). Over the next year, revenue is forecast to grow 17%, compared to a 37% growth forecast for the Healthcare Services industry in Australia. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Reported Earnings • Feb 28
First half 2022 earnings: EPS in line with expectations, revenues disappoint First half 2022 results: AU$0.002 loss per share (up from AU$0.031 loss in 1H 2021). Revenue: AU$14.4m (up 97% from 1H 2021). Net loss: AU$419.1k (loss narrowed 94% from 1H 2021). Revenue missed analyst estimates by 2.4%. Over the next year, revenue is forecast to grow 14%, compared to a 60% growth forecast for the industry in Australia. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth. Executive Departure • Oct 12
Company Secretary Jennifer Pilcher has left the company On the 1st of October, Jennifer Pilcher's tenure as Company Secretary ended after 3.4 years in the role. As of June 2021, Jennifer still personally held 571.52k shares (AU$609k worth at the time). Jennifer is the only executive to leave the company over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Reported Earnings • Feb 20
First half 2021 earnings released: AU$0.031 loss per share (vs AU$0.004 profit in 1H 2020) The company reported a poor first half result with weaker earnings, revenues and control over costs. First half 2021 results: Revenue: AU$7.10m (down 22% from 1H 2020). Net loss: AU$7.17m (down AU$7.85m from profit in 1H 2020). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 61% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 17
New 90-day high: AU$1.55 The company is up 30% from its price of AU$1.20 on 19 November 2020. The Australian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare Services industry, which is up 31% over the same period. Is New 90 Day High Low • Jan 21
New 90-day high: AU$1.34 The company is up 36% from its price of AU$0.98 on 23 October 2020. The Australian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$2.89 per share. Announcement • Nov 25
Mach7 Technologies Announces the Next Phase in Empowering AI Within Radiology Reading Workflow to Drive Better Clinical Outcomes Mach7 Technologies announced the start of the clinical validation phase for a new solution that integrates Mach7s advanced and zero-footprint eUnity Diagnostic Viewer within Nuance® Communication's cloud-hosted PowerScribe™ One radiology platform. Innovated in collaboration with Nuance, the integrated solution can accelerate the at-scale adoption of AI models from the Nuance AI Marketplace for Diagnostic Imaging within PowerScribe One reports for improved patient outcomes. The integrated solution intelligently launches the Mach7 eUnity Diagnostic Viewer within the radiologist's standard PowerScribe One workflow, pre-populating the report with data produced by AI models. The radiologist can then review and edit the AI results directly in the eUnity Diagnostic Viewer, with all findings and adjustments automatically updated in the report without requiring repeated dictation. That reduces turnaround times for reporting findings to referring physicians and improves radiology report accuracy and completeness. The Mach7 and Nuance collaboration's key goal is to give radiologists the ability to select AI solutions that provide previously unavailable results information and add meaningful clinical value to a patient's report. As part of the workflow innovation, radiologists can easily select which results are correct or need adjustment. That enables radiologists to provide the referring physician with easy access to images and findings, allowing for better care team communication on critical clinical issues within a study. In addition to the valuable clinical approach this collaboration brings, commercial AI developers can offer applications for a range of medical imaging findings and modalities through the Nuance AI Marketplace, simplifying access to these AI models. The AI Marketplace brings AI into the radiology workflow by connecting developers directly with radiology subscribers. It offers AI developers a single API to deliver their AI solutions to radiologists across the 8,000 healthcare facilities that use the Nuance PowerShare Network. It gives radiology subscribers a one-stop-shop to review, try, validate, and buy AI models, bridging the technology divide to make AI useful, usable, and used throughout the radiology workflow. Is New 90 Day High Low • Nov 17
New 90-day high: AU$1.18 The company is up 25% from its price of AU$0.94 on 19 August 2020. The Australian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$2.25 per share. Announcement • Nov 14
Mach7 Technologies Limited Signs 7 Year Contract with Trinity Health Mach7 Technologies Limited announced it has signed a seven-year contract with Trinity Health for the license and associated support services for its eUnity enterprise viewer. Mach7 has signed its first contract with Trinity for the license of its eUnity enterprise viewer, and to supply seven years of associated product support and maintenance. Trinity is the fifth largest healthcare Integrated Delivery Network (IDN) in the United States and this contract will see Mach7's eUnity enterprise viewer being installed across multiple facilities within Trinity's 92 hospitals located across 22 States. The software deployment will occur in stages as software licenses are ordered by Trinity. Mach7 expects to receive the first software license orders this quarter, and majority of license orders within this financial year. The associated software license revenue is likely to be recognised very shortly after the order is received - upon the license delivery and software deployment ("Deployment"). Support and maintenance fees will commence one year after Deployment and will continue for a period of six years. The total value of this contract is A$5.26 million. Trinity has developed a Unified Clinical Imaging Platform strategy that includes an enterprise viewer, diagnostic viewer, universal worklist and vendor neutral archive. With the signing of this Master License Agreement and subsequent order for the enterprise viewer, Mach7 and Trinity Health have developed a smooth ordering process for future purchases to complete this strategy. Is New 90 Day High Low • Sep 30
New 90-day high: AU$1.16 The company is up 18% from its price of AU$0.98 on 02 July 2020. The Australian market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 1.0% over the same period. Announcement • Aug 26
Mach7 Technologies Limited to Report Fiscal Year 2020 Results on Aug 27, 2020 Mach7 Technologies Limited announced that they will report fiscal year 2020 results at 10:03 PM, GMT Standard Time on Aug 27, 2020 
